We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

006360:KRXGS Engineering & Construction Corporation Analysis

Data as of 2026-07-23 - not real-time

₩34,400.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

GS Engineering & Construction trades at KRW 34,400, comfortably above its 20‑day (KRW 28,295) and 50‑day (KRW 28,878) SMAs, while the 14‑day RSI of 61.8 signals continued buying momentum without being overbought. The MACD histogram is strongly positive (≈ 376) and the signal line is bullish, reinforcing a short‑term upside bias. A DCF‑derived fair value of KRW 50,655 implies roughly 19% upside, outpacing the industry PE average of 31 and positioning the stock as potentially undervalued. However, revenue has contracted by 21.6% YoY, margins are thin (gross 10.6%, operating 2.8%, profit 0.55%) and the balance sheet is leveraged (debt‑to‑equity ≈ 115%).
The company generates solid free cash flow (KRW 596 B) and pays a 1.72% dividend with a 65% payout ratio, suggesting current dividend sustainability. Yet volatility is extreme (117% 30‑day) and beta is elevated (≈ 1.3), indicating heightened market sensitivity. Combined with cyclical construction exposure and regulatory headwinds, the upside from valuation must be weighed against the downside risk from earnings weakness and high leverage.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price approaching resistance near KRW 35,750
  • Strong MACD and RSI momentum
  • Elevated volatility and leverage

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF upside of ~19% versus current price
  • Positive free cash flow supporting dividend
  • Undervalued relative to industry PE

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Persistent revenue decline and thin margins
  • High debt‑to‑equity ratio limiting financial flexibility
  • Cyclical nature of construction sector

Key Metrics & Analysis

Financial Health

Revenue Growth-21.60%
Profit Margin0.55%
P/E Ratio7.5
ROE1.68%
ROA1.37%
Debt/Equity114.98
Op. Cash Flow₩793.2B
Free Cash Flow₩596.1B
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI61.8
Support₩22,350.00
Resistance₩35,750.00
MA 20₩28,295.00
MA 50₩28,878.00
MA 200₩24,594.65
MACDBullish
VolumeStable
Fear & Greed Index88.04

Valuation

Fair Value₩50,654.64
Target Price₩41,075.00
Upside/Downside19.40%
GradeUndervalued
TypeValue
Dividend Yield1.72%

Risk Assessment

Beta1.29
Volatility117.05%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.